Audrey Sigmund

Assistant Professor in Lymphoma @OSUHematology. @NUFeinbergMed alum. Interested in #lymsm #MedEd #WomenInMedicine #HemeSurvivorship. Views are my own.

[Toby Eyre @tobyeyre82]

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial - The Lancet https://t.co/bOPpKGjJVw

[Ajay Major, MD, MBA @majorajay]

Prebiopsy steroids & diagnostic yield in DLBCL #lymsm
- 320 pts
- diagnostic yield unchanged w/ steroids (83% vs 81%)
- no association w/ dose or duration
- no delay in time to treatment
- FNA way less diagnostic than excisional/incisional
- Core needle 12% less likely to be diagnostic
Useful real-world data for pts needing steroids before diagnosis
https://t.co/9ZkDXhwAuQ

[Eddie Cliff @Eddie_Cliff]

🚨Just out in @BrJHaem

Hodgkin lymphoma's new era: choosing between Nivo-AVD and BrECADD

We compare and contrast HD21 & SWOG1826, attempting to be as neutral and objective as possible

Which would you choose?

https://t.co/eU1mHBgsia #lymsm @mike_dickinson1

[JCO Oncology Practice @JCOOP_ASCO]

Imposter Syndrome, Burnout, and Maladaptive Perfectionism Among Oncology Professionals: A Global Cross-Sectional Study.

Read the full article. https://t.co/5YjUoEWn6k

[Women in Lymphoma - [email protected] @WomenInLymphoma]

TOMORROW we’re launching our DLBCL webinar series!
Join @PallawiTorkaMD and Emily Ayers as they tackle treatment decisions in older patients — a conversation we all need in real-world practice.
Register at the link below and save your spot! https://t.co/gi7j67Ml0Q

[Brigham Education Institute @BrighamBEI]

Join the #BrighamBEI for Leadership in #MedEd, a new 4 part series for medical educators looking to build leadership skills, think strategically, and advance their careers. Kicks off April 8!

Register: https://t.co/aXJp5yK8wZ

@BrighamFellows
@BrighamRadOnc
@harvardneuromds

[Graham Collins @graham74GC]

Zanwar et al - POD24 in WM.
• 253 pts all Rx with 1L BR
• 5y PFS / OS 65% / 87%
• CXCR4 mutn worse prog (med PFS 3.3 v 8.8y
• POD24 (11%) assoc inf OS 71 v 86%
Not surprising but good to have data.
#lymsm

https://t.co/Zw7OgzZWGT

[JAMA @JAMA_current]

💬 Viewpoint: Mass abstract submissions in #MedEd have led to inflated metrics, less meaningful research, and misaligned incentives for trainees and institutions.

https://t.co/3uSaoJd5Rs

[Graham Collins @graham74GC]

Y Wang et al - ritux Maint after 1L BR in MCL
• 703 pts with ORR to 1L BR at 3mo post
• retrospect
• 56% R Mx, 44% no Mx (similar features)
• landmark analy: med EFS 49.9 mo with Mx, 29.7mo without, also OS benefit.
Confirms role of MxR in MCL
#lymsm

https://t.co/zsaGK2dxO0

[Ajay Major, MD, MBA @majorajay]

The L-THORs (Lymphoma Translational Health Outcomes Researchers) assemble at #ASH25, presenting work in patient-reported outcomes and time toxicity! 🎉 #lymsm cc @ASH_hematology

[Graham Collins @graham74GC]

Herrera et al - 3y FU SWG 1826
- BV-AVD vs Nivo-AVD 1L III/IV Hodgkin
- PFS benefit signif: 82% vs 91%
- High & low PFS benefit
- Particularly striking benefit older pfs (& adolescents)
- No myeloid malig in either arm
Fantastic data with this regimen #ASH25 #lymsm

[NEJM @NEJM]

Bedside clinical skills have been diminished by an overreliance on technology. A new Review Article presents educational strategies for reinvigorating the bedside encounter and shows how much can be learned from it.

Read the review “Strategies to Reinvigorate the Bedside Clinical Encounter,” the latest in the Medical Education series, by Brian T. Garibaldi, MD, MEHP, and Stephen W. Russell, MD, from @NUFeinbergMed and the University of Alabama at Birmingham (@UABNews): https://t.co/7IF47hAwzR

[OncLive.com @OncLive]

Learn more about clinical outcomes with a treatment option for 3L+ DLBCL adult patients. Click here https://t.co/RYRWtNdb6r to discover clinical trial efficacy, safety data, dosing, monitoring & management considerations for select adverse reactions, and more.

[GELTAMO @geltamo]

Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics | Blood Advances | American Society of Hematology https://t.co/CTuNvaoCG6

[Toby Eyre @tobyeyre82]

Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma https://t.co/B3AtRgYd6e

[Toby Eyre @tobyeyre82]

Optimising treatment strategies in older patients with mantle cell lymphoma - The Lancet https://t.co/0OQPzhxreL

[Carla Casulo, MD @DrCarlaCasulo]

Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? https://t.co/rFW0XwVqPT
Wonderful to work with Dr Laurie Sehn on this review highlighting our approach to relapsed FL #lymsm @BloodPortfolio @WilmotCancer

[Kate Cwynarski @CwynKate]

Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology | Blood Advances | American Society of Hematology https://t.co/L6zjWfQdbO

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell #Lymphoma #DLBCL | Journal of Clinical Oncology ⁦@JCO_ASCO⁩ #lymsm https://t.co/x3ZFTVtJwK

[Toby Eyre @tobyeyre82]

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study https://t.co/Bs0Tb04I6V